Ryman Healthcare Ltd
NZX:RYM

Watchlist Manager
Ryman Healthcare Ltd Logo
Ryman Healthcare Ltd
NZX:RYM
Watchlist
Price: 2.1 NZD -5.41% Market Closed
Market Cap: 2.1B NZD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

RYM Price Targets Summary
Ryman Healthcare Ltd

Wall Street analysts forecast RYM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RYM is 3.75 NZD with a low forecast of 3.27 NZD and a high forecast of 4.94 NZD.

RYM Lowest Forecast
Wall Street Target
3.27 NZD
56% Upside
RYM Average Forecast
Wall Street Target
3.75 NZD
78% Upside
RYM Highest Forecast
Wall Street Target
4.94 NZD
135% Upside
Lowest
Price Target
3.27 NZD
56% Upside
Average
Price Target
3.75 NZD
78% Upside
Highest
Price Target
4.94 NZD
135% Upside
Ryman Healthcare Ltd Competitors:
Price Targets
SIA
Sienna Senior Living Inc
9% Upside
MEDICAB
Medica Sur SAB de CV
70% Upside
RDOR3
Rede D'Or Sao Luiz SA
8% Upside
MPARK.E
MLP Saglik Hizmetleri AS
75% Upside
SIA
Sienna Senior Living Inc
9% Upside
MEDICAB
Medica Sur SAB de CV
70% Upside
RDOR3
Rede D'Or Sao Luiz SA
8% Upside
MPARK.E
MLP Saglik Hizmetleri AS
75% Upside
P
PR9
Praram 9 Hospital PCL
23% Upside
EHC
Encompass Health Corp
10% Upside

Revenue
Forecast

Revenue Estimate
Ryman Healthcare Ltd

For the last 13 years the compound annual growth rate for Ryman Healthcare Ltd's revenue is 13%. The projected CAGR for the next 2 years is 10%.

13%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Ryman Healthcare Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-79%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Ryman Healthcare Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

See Also

Summary
RYM intrinsic value, competitors valuation, and company profile.
DCF Valuation
RYM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RYM stock valuation using valuation multiples.
Wall Street Estimates
RYM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RYM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RYM's stock price target?
Price Target
3.75 NZD

According to Wall Street analysts, the average 1-year price target for RYM is 3.75 NZD with a low forecast of 3.27 NZD and a high forecast of 4.94 NZD.

What is Ryman Healthcare Ltd's Revenue forecast?
Projected CAGR
10%

For the last 13 years the compound annual growth rate for Ryman Healthcare Ltd's revenue is 13%. The projected CAGR for the next 2 years is 10%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.